PTAB Considers Discretionary Denial Based on Parallel ITC Investigation, After Withdrawal of Fintiv Memo

May 9, 2025

Reading Time : 2 min

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

The patent at issue was directed to a photosensitive device capable of detecting visible and infrared electromagnetic radiation. Petitioner filed a petition for IPR challenging the patentability of several claims. Prior to the IPR, patent owner had asserted the patent against petitioner at the ITC and in district court. The ITC investigation was ongoing, but, as is customary, the district court case was stayed pending the conclusion of the ITC investigation. Patent owner argued in the IPR that the board should deny the petition under Fintiv because institution would incur significant inefficiencies and risk inconsistent outcomes. The board analyzed each of the six Fintiv factors in turn.

The board determined that factors two, three, and five weighed in favor of discretionary denial.  In reaching that finding, the board noted that the ITC investigation had a target completion date more than three months before the statutory deadline for a final written decision in the IPR, the ITC had already completed substantial work, and the parties were the same in the IPR and the ITC investigation. Factor one—whether there is a stay in the parallel proceedings—was neutral. Although there was a stay in the district court, there was no stay for the ITC investigation. The board noted that the lack of a stay for the ITC investigation elevated the importance of factor four, which concerns overlap between issues raised in the petition and parallel proceedings.

Regarding factor four, patent owner initially argued that the validity issues presented were nearly identical at the PTAB and in the ITC. Petitioner responded by withdrawing a ground from the IPR petition that overlapped with the ITC investigation and stipulating that “if the [b]oard institutes this IPR on the two remaining applicable grounds, petitioner will not assert invalidity in parallel litigation using as primary or combination references any of the references asserted in those grounds.” The board thereafter determined that the record no longer supported that the ITC would adjudicate the invalidity grounds raised in the petition and therefore factor four weighed against discretionary denial. The board also determined that “other considerations” under factor six weighed against denial, including that the petition’s merits were strong and that the narrowing of the petition minimized the burden on the parties and the board. 

In considering the factors as a whole, the board ultimately concluded that the strength of the merits and lack of overlap in proceedings outweighed any potential inefficiencies and declined to exercise its discretion in this situation.

Practice Tip:

In light of the withdrawal of the June 21, 2022 Fintiv Memo, patent owners faced with an IPR should now consider arguing for discretionary denial under Fintiv where there is a parallel ITC investigation.  Conversely, petitioners seeking to avoid discretionary denial should consider taking steps to minimize overlap between unpatentability grounds in a petition and invalidity positions taken in parallel proceedings.


Samsung Elecs. Co., Ltd. v. Sionyx, LLC, IPR2024-01431, Paper 21 (P.T.A.B. Apr. 10, 2025)

Share This Insight

Previous Entries

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

IP Newsflash

June 26, 2025

The Northern District of Ohio denied a motion to compel the plaintiff to produce test results referenced in its initial disclosures and complaint. The court found that because the “test results are not facts but rather are opinions,” the information was protected as work product. Furthermore, because that testing would not be used as evidence in the litigation, the defendant was not prejudiced.

...

Read More

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.